CSBio CSBio

X
[{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Department of Health - Abu Dhabi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Health - Abu Dhabi, M42 and AbbVie Enter a Strategic Partnership to Advance Personalised Medicine and Genomics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"AbbVie Inc"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Stand Up To Cancer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Jazz Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement aims to advance personalised, genomics and precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.

            Lead Product(s): Precision Medicine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Department of Health - Abu Dhabi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 19, 2023

            Abbvie Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The collaboration will provide SU2C-funded researchers access to two Jazz molecules and funds to support one or more research projects over three years. One of the projects would help explore clinical use of lurbinectedin in rare and hard to treat pediatric solid tumors.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Stand Up To Cancer

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY